Active, not recruitingPhase 2NCT04931342
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
Studying Rare ovarian cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoffmann-La Roche
- Principal Investigator
- Clinical TrialsHoffmann-La Roche
- Intervention
- Ipatasertib(drug)
- Enrollment
- 176 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2021 – 2028
Study locations (20)
- UCSF Helen Diller Family CCC, San Francisco, California, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Levine Cancer Institute, Charlotte, North Carolina, United States
- Ohio State University, Columbus, Ohio, United States
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
- Texas Oncology - Gulf Coast, The Woodlands, Texas, United States
- Virginia Oncology Associates, Norfolk, Virginia, United States
- University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States
- Cabrini Hospital, Malvern, Victoria, Australia
- Princess Margaret Cancer Center, Toronto, Ontario, Canada
- McGill University Health Centre - Glen Site, Montreal, Quebec, Canada
- Gynekologicko-porodnicka klinika, Prague, Czechia
- CHU Besançon - Hôpital Jean Minjoz, Besançon, France
- Centre Francois Baclesse, Caen, France
- Centre Leon Berard, Lyon, France
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04931342 on ClinicalTrials.gov